Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract
El-Ashmawy, N., Zakaria, F., Al-Ashmawy, G., Hamouda, S. (2021). Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract. EKB Journal Management System, 5(0), 20-20. doi: 10.21608/jcbr.2021.60072.1153
Nahla El-Ashmawy; Fatma Zakaria; Ghada Al-Ashmawy; Sara Mohamed Hamouda. "Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract". EKB Journal Management System, 5, 0, 2021, 20-20. doi: 10.21608/jcbr.2021.60072.1153
El-Ashmawy, N., Zakaria, F., Al-Ashmawy, G., Hamouda, S. (2021). 'Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract', EKB Journal Management System, 5(0), pp. 20-20. doi: 10.21608/jcbr.2021.60072.1153
El-Ashmawy, N., Zakaria, F., Al-Ashmawy, G., Hamouda, S. Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract. EKB Journal Management System, 2021; 5(0): 20-20. doi: 10.21608/jcbr.2021.60072.1153

Evaluation of the use of long noncoding RNAs as biomarkers for diagnosis of breast cancer: Thesis Abstract

Egyptian Journal of Cancer and Biomedical Research
Article 22, Volume 5, Issue 0, May 2021, Page 20-20  XML PDF (189.5 K)
Document Type: Essay Abstract
DOI: 10.21608/jcbr.2021.60072.1153
View on SCiNiTO View on SCiNiTO
Authors
Nahla El-Ashmawy1; Fatma Zakaria2; Ghada Al-Ashmawyorcid 3; Sara Mohamed Hamouda email orcid 4
1Professor of Biochemistry and Dean of the Faculty of Pharmacy, Faculty of Pharmacy, Tanta University
2Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
3Department of Biochemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
4Biochemistry department, Faculty of pharmacy, Tanta university, Tanta, Egypt
Abstract
Background: FAM83H antisense RNA 1 (FAM83H-AS1) and long noncoding RNA activated by TGF β (lncRNA-ATB) are two lncRNAs that have tumor promoting functions in breast cancer (BC). Matrix metalloproteinase-9 (MMP-9) is another tumor marker that exerts an oncogenic role in BC and facilitate cancer invasion and metastasis. Aims: Our study aimed to 1) analyze serum levels of FAM83H-AS1, lncRNA-ATB, and MMP-9 in BC patients, 2) compare their diagnostic role with that of CA15-3 in BC patients with different stages (I-II, III, and IV), and 3) correlate the levels of the measured lncRNAs, MMP-9, and CA15-3 with the clinicopathological features of BC. Materials and Methods: Serum FAM83H-AS1 and lncRNA-ATB levels were analyzed in 90 BC patients and 30 healthy controls using RT-PCR. While serum levels of MMP-9 and CA15-3 were measured in the same studied groups by ELISA. Results: FAM83H-AS1, lncRNA-ATB, MMP-9, and CA15-3 levels were significantly elevated in sera of BC patients. ROC curve analysis showed that lncRNA-ATB and MMP-9 had higher AUC values than CA15-3 in diagnosis of stage I-II patients (AUC: 0.844 and 0.898, p= 0.000 for lncRNA-ATB and MMP-9, respectively versus 0.738, p= 0.002 for CA15-3). FAM83H-AS1 level was significantly correlated with higher stage, larger tumor size, positive lymph node metastasis, and distant metastasis. FAM83H-AS1 level was also significantly increased in PR-negative and ki67-rich tumors. Conclusion: Our study demonstrated that circulating lncRNA-ATB and MMP-9 could be used as diagnostic biomarkers for early BC. FAM83H-AS1 could also be a potential candidate for staging BC and monitoring disease progression.
Keywords
Breast cancer diagnosis; FAM83H-AS1; LncRNA-ATB; Long non-coding RNA; MMP-9
Statistics
Article View: 382
PDF Download: 177